Funding for this research was provided by:
Center for Strategic Scientific Initiatives, National Cancer Institute (R01 CA-204373, R01 CA-075059)
Article History
Received: 12 April 2018
Revised: 23 July 2018
Accepted: 24 July 2018
First Online: 6 September 2018
Conflict of interest
: Y.S.: patents around tetrahydrouridine, decitabine, 5-azacytidine and ISWI corepressor inhibition; consultancy, ownership and royalty eligibility through EpiDestiny. The remaining authors declare that they have no conflict of interest.